SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Credit Suisse 26th Annual Healthcare Conference in Scottsdale, Arizona. The live presentation takes place on Wednesday, November 8 at 9:30am ET ( 6:30am PT). The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for one month. About Neurocrine Biosciences Neurocrine Biosciences is a San Diego based biotechnology company focused on neurologic, psychiatric and endocrine related disorders. The Company markets INGREZZA ® (valbenazine) capsules in the United States for the treatment of adults with tardive dyskinesia. INGREZZA is a novel, selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the first FDA approved product indicated for the treatment of adults with tardive dyskinesia. The Company's three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women's health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson's patients; and INGREZZA, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette syndrome. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com. View original content: http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-credit-suisse-26th-annual-healthcare-conference-300546493.html SOURCE Neurocrine Biosciences, Inc.